Literature DB >> 25478521

Left Main PCI, Still a Main Issue.

Farshad Shakerian1.   

Abstract

Entities:  

Keywords:  Drug- Eluting Stent; Left main; Stenting

Year:  2013        PMID: 25478521      PMCID: PMC4253782          DOI: 10.5812/cardiovascmed.14740

Source DB:  PubMed          Journal:  Res Cardiovasc Med        ISSN: 2251-9572


× No keyword cloud information.
In this issue of journal, we have an observational study on left main PCI, a hot debate in interventional cardiology field (1). They reported that MACCE rate of 22% in one year follow-up seems to be pretty high. Several flaws make the interpretation of the results difficult. First and foremost, how could you mix protected and unprotected LM stenting together? Most of the unprotected ones didn’t have a better option, but protected LM stenting should be compared with other options: the good old CABGs. As far as I’m concerned, most of unprotected LM PCIs were done because of LM dissection or emergent conditions which make the results even more complicated. Using so many bare metal stents in this significant place again shows the emergency situation of the condition which was not stated. One year follow-up is not enough but still the MACCE rate is high. I mean if we had longer follow-up, higher figures where expected (2-4). Considering descriptive type of the study and mixing so many different types of patient subgroups which are actually completely different (protected and unprotected, emergent & elective, BMS & DES) makes the results uniterpretable. Using BMS in LM is not ethical in elective cases and I think they have used them in emergency situations. This further implies the inability to compare results (5, 6). Protected LM (includes most cases which is completely another issue and putting it together with unprotected cases is mixing two mutually exclusive issues). Although LM atherosclerosis seems to be responsive to risk factor modification and more or less under influence of the same factors as other vessels are, it has some different characteristics (7). The main difference is the presence of a large side branch (if we could call Left circumflex a side branch!) which makes the most interventions on LM, a bifurcation lesion. As most of bifurcations happens, ostium of circumflex shows the highest rate of restenosis unless you use two stents which makes the procedure cumbersome (8, 9). In the end, I would like to stick to the latest RCTs and do recommend PCI for low risk anatomy with good SYNTAX score and surgery for the others.
  9 in total

1.  Preprocedural levels of C-reactive protein and leukocyte counts predict 9-month mortality after coronary angioplasty for the treatment of unprotected left main coronary artery stenosis.

Authors:  Tullio Palmerini; Antonio Marzocchi; Cinzia Marrozzini; Paolo Ortolani; Francesco Saia; Letizia Bacchi-Reggiani; Santo Virzì; Silvia Gianstefani; Angelo Branzi
Journal:  Circulation       Date:  2005-10-03       Impact factor: 29.690

2.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

Authors:  Steven R Steinhubl; Peter B Berger; J Tift Mann; Edward T A Fry; Augustin DeLago; Charles Wilmer; Eric J Topol
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

3.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

Authors:  S R Mehta; S Yusuf; R J Peters; M E Bertrand; B S Lewis; M K Natarajan; K Malmberg; H Rupprecht; F Zhao; S Chrolavicius; I Copland; K A Fox
Journal:  Lancet       Date:  2001-08-18       Impact factor: 79.321

4.  Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation.

Authors:  Seung-Jung Park; Young-Hak Kim; Bong-Ki Lee; Seung-Whan Lee; Cheol Whan Lee; Myeong-Ki Hong; Jae-Joong Kim; Gary S Mintz; Seong-Wook Park
Journal:  J Am Coll Cardiol       Date:  2005-02-01       Impact factor: 24.094

5.  Early and mid-term results of drug-eluting stent implantation in unprotected left main.

Authors:  Alaide Chieffo; Goran Stankovic; Erminio Bonizzoni; Eleftheria Tsagalou; Ioannis Iakovou; Matteo Montorfano; Flavio Airoldi; Iassen Michev; Massimo Giuseppe Sangiorgi; Mauro Carlino; Giancarlo Vitrella; Antonio Colombo
Journal:  Circulation       Date:  2005-02-07       Impact factor: 29.690

6.  Rapamycin-eluting stents for the treatment of unprotected left main coronary disease.

Authors:  Jose Suarez de Lezo; Alfonso Medina; Manuel Pan; Antonio Delgado; José Segura; Djordje Pavlovic; Francisco Melián; Miguel Romero; Luis Burgos; Enrique Hernández; Isabel Ureña; Juan Herrador
Journal:  Am Heart J       Date:  2004-09       Impact factor: 4.749

7.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

Authors:  Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

8.  TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions.

Authors:  Eberhard Grube; Sigmund Silber; Karl Eugen Hauptmann; Ralf Mueller; Lutz Buellesfeld; Ulrich Gerckens; Mary E Russell
Journal:  Circulation       Date:  2003-01-07       Impact factor: 29.690

9.  Evaluation of Percutaneous Coronary Intervention and stenting of Left Main Coronary Artery Stenosis in Tehran's Rajaie and Lavasani Hospitals from 2010 to 2011.

Authors:  Safarali Abdolrahimi; Hamidreza Sanati; Alireza Fatahian
Journal:  Res Cardiovasc Med       Date:  2013-10-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.